DTaP vaccine paediatric - GlaxoSmithKline

Drug Profile

DTaP vaccine paediatric - GlaxoSmithKline

Alternative Names: Diphtheria tetanus-acellular pertussis vaccine - GlaxoSmithKline; Infanrix

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 10 Jul 2003 The FDA approved Infanrix® as the fifth consecutive dose in the paediatric vaccination schedule
  • 02 Mar 2001 GlaxoSmithKline has applied to the US FDA for approval of Infanrix® as the fifth consecutive dose in the paediatric vaccination schedule
  • 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top